A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Inclusion Criteria:

- Age >/= 18 years

- ECOG score of 0-1

- One of the following histologically-documented hematologic malignancies for which no
effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), follicular
lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or
chronic lymphocytic leukemia (CLL)

- At least one site of disease that, as seen on CT scan, is > 1.5 cm in the greatest
transverse diameter or > 1.0 cm in short axis diameter (except for patients with CLL)

- An available tumor specimen

- Adequate hematologic and organ function

- For female patients of childbearing potential and male patients with partners of
childbearing potential, use of effective contraceptive(s) as defined by protocol for
the duration of the study

Exclusion Criteria:

- Life expectancy < 12 weeks

- < 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic,
experimental, hormonal or radiotherapy (with the exception of leuprolide or similar
medications for prostate cancer)

- Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds

- Active infection requiring IV antibiotics

- Clinically significant history of liver disease, including viral or other hepatitis,
current alcohol abuse, or cirrhosis.

- Primary CNS malignancy or untreated/active CNS metastases (progressing or requiring
anticonvulsants or corticosteroids for symptomatic control)

- History of other malignancy within 5 years prior to screening, except for
appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, Stage
I uterine cancer, or other cancers with a similar outcome

- Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for
ventricular dysrhythmias

- Pregnancy, or lactation

- Any other diseases that contraindicates the use of an investigational drug or that may
affect the interpretation of the results or render the patient at high risk from
treatment complications